1. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020.
- Author
-
Davis, Greg, York, Allen J., Bacon, Willis Clark, Lin, Suh-Chin, McNeal, Monica Malone, Yarawsky, Alexander E., Maciag, Joseph J., Miller, Jeanette L. C., Locker, Kathryn C. S., Bailey, Michelle, Stone, Rebecca, Hall, Michael, Gonzalez, Judith, Sproles, Alyssa, Woodle, E. Steve, Safier, Kristen, Justus, Kristine A., Spearman, Paul, Ware, Russell E., and Cancelas, Jose A.
- Subjects
COVID-19 ,SARS-CoV-2 ,COVID-19 pandemic ,SEROPREVALENCE ,HERD immunity ,IMMUNOGLOBULIN G ,VIRAL antibodies - Abstract
The world is currently in a pandemic of COVID-19 (Coronavirus disease-2019) caused by a novel positive-sense, single-stranded RNA β-coronavirus referred to as SARS-CoV-2. Here we investigated rates of SARS-CoV-2 infection in the greater Cincinnati, Ohio, USA metropolitan area from August 13 to December 8, 2020, just prior to initiation of the national vaccination program. Examination of 9,550 adult blood donor volunteers for serum IgG antibody positivity against the SARS-CoV-2 Spike protein showed an overall prevalence of 8.40%, measured as 7.56% in the first 58 days and 9.24% in the last 58 days, and 12.86% in December 2020, which we extrapolated to ~20% as of March, 2021. Males and females showed similar rates of past infection, and rates among Hispanic or Latinos, African Americans and Whites were also investigated. Donors under 30 years of age had the highest rates of past infection, while those over 60 had the lowest. Geographic analysis showed higher rates of infectivity on the West side of Cincinnati compared with the East side (split by I-75) and the lowest rates in the adjoining region of Kentucky (across the Ohio river). These results in regional seroprevalence will help inform efforts to best achieve herd immunity in conjunction with the national vaccination campaign. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF